ClinicalTrials.gg
CompletedNCT04781114Updated Apr 19, 2023

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

A Phase 3 interventional study of JS002 and Placebo in Hyperlipemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 57 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
806
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Hyperlipidemias with a site in China — 31 open to participants now, 39 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
10th of 80
806 · median 155
Started
2020
with 8 others
Phase 3
20 of 96
4 open now
Registered
31st of 96
by date
Lead sponsor
5 of 96
Shanghai Junshi Bioscience Co., Ltd.

Among the 96 studies in Hyperlipidemias with a site in China, this one is the 10th largest by enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2020, is one of 20 in phase 3, and was the 31st registered.

Hyperlipidemias

864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

31 of the 96 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients with hyperlipidemia when combined with statin therapy.

In this study, two dose group (150 mg, 300 mg) were set up in this study. 750 subjects are plan to be enrolled (the study drug will be assigned to a 2:1 ratio of JS002 or placebo).

Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest. Use a bulleted list for each criterion below the headers "Inclusion Criteria" and "Exclusion Criteria". (Limit: 15,000 characters.) Inclusion criteria

  1. Males and females ≥ 18 and ≤ 80 years of age;
  2. LDL_C during screening period met the following conditions: super high risk: LDL - C ≥1.4mmol/L (55 mg/dL); extremely high risk: LDL - C ≥1.8 mmol/L (70 mg/dL); risk: LDL - C ≥2.6 mmol/L (100 mg/dL); low risk: LDL - C ≥ 3.4 /mmol/L (130 mg/dL)
  3. Fasting triglycerides ≤4.5 mmol/L;

Exclusion criteria

  1. Known HoFH;
  2. History of class III-IV heart failure;
  3. History of uncontrolled arrhythmia, Unstable angina,MI, PCI,CABG, DVT or pulmonary embolism within 3 months.
  4. Uncontrolled hypertension.
  5. Uncontrolled diabetes mellitius (>8.0%).
  6. Other conditions that investigators considered inappropriate to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
806 participants (actual)

Study arms

  • Experimental
    JS002

    Cohort 1: 150 mg/1mL Q2W Subcutaneous(SC); Cohort 2: 300/2mL mg Q4W Subcutaneous(SC);

    Drug: JS002

  • Placebo comparator
    Placebo

    Cohort 1: 1mL Q2W Subcutaneous(SC); Cohort 2: 2mL Q4W Subcutaneous(SC);

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in LDL-C of JS002

    Percentage change in LDL-C relative to baseline at Week 24

    Time frame: Up to 24Weeks after dose administration

Secondary outcomes

  1. Change in LDL-C of JS002

    Percentage change in LDL-C relative to baseline at Week 52

    Time frame: Up to 52Weeks after dose administration

  2. Other lipid parameters of JS002

    Percentage change in LDL-C relative to baseline at Week 24 and Week 52

    Time frame: Up to Week 24 and 52Weeks after dose administration

  3. The occurrence of adverse events

    Evaluate the change of clinically significant laboratory tests, vital signs, and electrocardiogram

    Time frame: Up 60Weeks after dose administration

  4. The immunogenicity of JS002

    To evaluate the production time, duration and proportion of anti JS002 antibody (ADA).ADA positive samples are tested for titer and for neutralizing antibody (Nab).

    Time frame: Up 60Weeks after dose administration

  5. Pharmacokinetics (PK) of JS002

    Evaluation of Serum concentration of JS002.Descriptive statistics include mean (arithmetic mean and geometric mean), standard deviation (SD), coefficient of variation CV% (arithmetic coefficient and geometric coefficient of variation), Median (Median), minimum (Min) and maximum (Max).

    Time frame: Up 60Weeks after dose administration

  6. Pharmacokinetics (PD) of JS002

    Evaluation of serum concentrations of free/total PCSK9 and changes from baseline.Descriptive statistics include mean (arithmetic mean and geometric mean), standard deviation (SD), coefficient of variation CV% (arithmetic coefficient and geometric coefficient of variation), Median (Median), minimum (Min) and maximum (Max).

    Time frame: Up 60Weeks after dose administration

07

Study locations

57 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing 100000, China
  • Beijing Chaoyang Hospital, Capital Medical University
    Beijing, Beijing 100000, China
  • Beijing Tongren Hospital Affiliated to Capital Medical University City:Beijing
    Beijing, Beijing 100000, China
  • China-Japan Friendship Hospital
    Beijing, Beijing 100000, China
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
  • The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China
    Fuzhou, Fujian 350000, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350000, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730000, China
  • The First Hospital of Lanzhou University City:Lanzhou
    Lanzhou, Gansu 730000, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 5100000, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510000, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518000, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530000, China
  • Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550000, China
  • Hainan General Hospital
    Haikou, Hainan 570100, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Daqingshi People's Hospital
    Daqing, Heilongjiang 163316, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Haerbin, Heilongjiang 15000, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434000, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410100, China
  • The Second People's Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Zhongda Hospital Southeast Universty
    Nanjing, Jiangsu 210009, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
  • The First Hospital of Nanchang
    Nanchang, Jiangxi 330000, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
  • First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin 130033, China
  • The central hospital of Dalian
    Dalian, Liaoning 116000, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning 121000, China
  • The People's Hospital of Liaoning Provincial
    Shenyang, Liaoning 110000, China
  • General Hospital of the PLA Northern Theater Command
    Shenyang, Liaoning 110020, China
  • Jinan Central Hospital
    Jinan, Shandong 250000, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200000, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200000, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai 200000, China
  • Shanghai East Hospital
    Shanghai, Shanghai 200000, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030000, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 030000, China
  • Xianyang Hospital of Yan 'an University
    Xianyang, Shanxi 712000, China
  • The First Affiliated Hospital of the Air Force Medical University
    Xian, Shanxi 710000, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xian, Shanxi 710000, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
  • Teda International Cardiovascular Hospital
    Tianjin, Tianjin 300000, China
  • Tianjin First Central Hospital
    Tianjin, Tianjin 300000, China
  • Tianjin People's Hospital
    Tianjin, Tianjin 300000, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 318000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2022, 17 months.

Of 57 phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Mar 4, 2021
StartActual
Dec 23, 2020
Primary completionActual
May 25, 2022
CompletionActual
Jan 16, 2023
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04781114
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Dec 23, 2020
Primary completion
May 25, 2022
Completion
Jan 16, 2023
Last update
Apr 19, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion